论文部分内容阅读
为观察二甲双胍对糖耐量减低（ＩＧＴ）患者糖代谢、胰岛素敏感性及其转归的影响，对７０例ＩＧＴ患者进行为期１年的双盲和对照性二甲双胍治疗研究。结果：治疗组１年期间转变为糖尿病（ＤＭ）者１例（３．０％），维持ＩＧＴ者４例（１２．１％），转变为正常者２８例（８４．９％），而对照组上述病例数分别为６（１６．２％），１２（３２．４％）和１９（５１．４％），Ｐ＝０．０１１。与对照组相比，二甲双胍治疗能改善空腹血糖、胰岛素敏感指数，降低尿白蛋白排泄率、腰围／臀围比值和体重指数，差异均有显著性意义（Ｐ＜０．０５）。上述结果提示二甲双胍可用于ＩＧＴ患者的干预治疗
To investigate the effect of metformin on glycometabolism, insulin sensitivity and outcome in patients with impaired glucose tolerance (IGT), a one-year double-blind and controlled metformin study of 70 patients with IGT was performed. Results: One patient (3.0%) in the treatment group changed to diabetes (DM) in one year, four patients (12.1%) maintained IGT and 28 patients (84.9%) changed to normal, while the control The above cases were 6 (16.2%), 12 (32.4%) and 19 (51.4%), respectively, P = 0.011. Compared with the control group, metformin treatment can improve fasting blood glucose, insulin sensitivity index, reduce urinary albumin excretion rate, waist / hip ratio and body mass index, the difference was significant (P <0.05). These results suggest that metformin can be used in IGT patients intervention